Gaurav Luthria

Gaurav Luthria

Auto-generated profile, based on publicly available information

Gaurav Luthria

Stanford University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2018 in ACS Nano
Verified
Journal Article
Open access
MMMiles Miller
Miles Miller
HMHannes Mikula
Hannes Mikula
GLGaurav Luthria
Gaurav Luthria
RLRan Li
Ran Li
SKStefan Kronister
Stefan Kronister
RWRalph Weissleder
Ralph Weissleder
Prodrug strategies that facilitate localized and controlled activity of small-molecule therapeutics can reduce systemic exposure and improve pharmacokinetics, yet limitations in activation chemistry have made it difficult to assign tunable multifunctionality to prodrugs. Here, we present the design and application of a modular small-molecule caging strategy that couples bioorthogonal cleavage with a self-immolative linker and an aliphatic anchor. This strategy leverages recently discovered in vivo catalysis by a nanoencapsulated palladium compound (Pd-NP), which mediates alloxylcarbamate cleavage and triggers release of the activated drug. The aliphatic anchor enables >90% nanoencapsulation efficiency of the prodrug, while also allowing >104-fold increased cytotoxicity upon prodrug activation. We apply the strategy to a prodrug formulation of monomethyl auristatin E (MMAE), demonstrating its ability to target microtubules and kill cancer cells only after selective activation by Pd-NP. Computational pharmacokinetic modeling provides a mechanistic basis for the observation that the nanotherapeutic prodrug strategy can lead to more selective activation in the tumor, yet in a manner that is more sensitive to variable enhanced permeability and retention (EPR) effects. Combination treatment with the nanoencapsulated MMAE prodrug and Pd-NP safely blocks tumor growth, especially when combined with a local radiation therapy regimen that is known to improve EPR effects, and represents a conceptual step forward in prodrug design.

22 May 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
SWStephanie J. Wang
Stephanie J. Wang
RLRan Li
Ran Li
TNThomas Ng
Thomas Ng
GLGaurav Luthria
Gaurav Luthria
MOMadeleine Oudin
Madeleine Oudin
MMMiles Miller
Miles Miller
Combining multicellular signaling profiles with in vivo imaging reveals how nanotherapy can block local resistance pathways.

14 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
GLGaurav Luthria
Gaurav Luthria
RLRan Li
Ran Li
SWStephanie Wang
Stephanie Wang
MPMark Prytyskach
Mark Prytyskach
RKRainer H. Kohler
Rainer H. Kohler
MMMiles Miller
Miles Miller
Microtubules (MTs) mediate mitosis, directional signaling, and are therapeutic targets in cancer. Yet in vivo analysis of cancer cell MT behavior within the tumor microenvironment remains challenging. Here we developed an imaging pipeline using plus-end tip tracking and intravital microscopy to quantify MT dynamics in live xenograft tumor models. Among analyzed features, cancer cells in vivo displayed higher coherent orientation of MT dynamics along their cell major axes compared with 2D in vitro cultures, and distinct from 3D collagen gel cultures. This in vivo MT phenotype was reproduced in vitro when cells were co-cultured with IL4-polarized MΦ. MΦ depletion, MT disruption, targeted kinase inhibition, and altered MΦ polarization via IL10R blockade all reduced MT coherence and/or tumor cell elongation. We show that MT coherence is a defining feature for in vivo tumor cell dynamics and migration, modulated by local signaling from pro-tumor macrophages.

8 May 2021 in Current Opinion in Systems Biology
Verified
Journal Article
Closed access
GLGaurav Luthria
Gaurav Luthria
DLDouglas Lauffenburger
Douglas Lauffenburger
MMMiles Miller
Miles Miller

6 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ACAudris Chiang
Audris Chiang
GSGayathri Swaminathan
Gayathri Swaminathan
GLGaurav Luthria
Gaurav Luthria
MHMarlayna Harris
Marlayna Harris
HSHaniyah Shareef
Haniyah Shareef
KSKavita Y. Sarin
Kavita Y. Sarin
Identifying inherited cancer predisposition genes remains challenging. We leveraged the skin’s high UV-mutagenic burden to discover susceptibility genes by studying patients with high frequency of basal cell carcinomas (hfBCC). We found that hfBCC patients had three-fold higher internal malignancy prevalence and identified a novel candidate EPHB2 cancer susceptibility mutation associated with BCC and prostate cancer. These findings demonstrate the skin’s potential as a powerful platform for discovering cancer predisposition variants.